Sunday, November 22, 2026
20 C
Bengaluru

Does India Need to Reinvent the Wheel on Junk Foods?

In a written reply in the Lok Sabha in early August 2026, Minister of State for Health Prataprao Jadhav stated that the Indian Council of Medical Research (ICMR) has not conducted any study to assess whether ultra-processed foods (UPFs) exhibit addiction-like behavioural characteristics comparable to tobacco products or other habit-forming substances.

At the same time, the Minister noted that, based on available global scientific evidence, ICMR has indicated that higher consumption of UPFs is associated with an increased risk of adverse health outcomes, including obesity, type 2 diabetes, cardiovascular diseases and mental disorders. These conditions are multifactorial in origin, and high UPF intake is considered one of several modifiable risk factors. The available evidence is largely observational and does not, by itself, establish causality.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Topics

USFDA Crackdown on Indian Pharma: Lessons for Indian Regulator

The US Food and Drug Administration has made unannounced...

The era of regulatory arbitrage in Indian nutraceuticals is officially over.

With the FSSAI suspending licenses across six nutraceutical manufacturers...

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...
spot_img

Related Articles

spot_imgspot_img